A relationship with a very large fund that is interested in acquiring 100% or substantial controling interest in Asian companies in the food/agriculture space, with a preference for Chinese companies. They're interested in companies with minimum EBITDA of $15mm as they want to put no less than $50mm (up to $200mm)to work per transaction.

http://sumfolio.com/powerful-potential-at-china-sun-group-083/

CSGH

The 7 Reasons Why You Should be
Bullish on China...

1 of every 5 people in the world live there

100 cities with over 1 million people (only 9 in the U.S.)

300 million people under age 14 representing future consumers who want a standard of living similar to that of Western societies

#1 market for mobile phones with 461 million users (larger than the entire U.S. population)

#2 market for Internet users at 137 million, and growing despite pervasive censorship

GDP growth average 9.37% per year for the last 25 years running

A central government committed to lifting the masses to a consumption driven middle and upper class status in one generation

CSGH to uplist to NYSE...from TheStreet.com interview with the CEO in China:

"We are highly confident that the testing will be completely successful. The testing involves repeated charging and discharging of batteries, which in the past would take up to 50 weeks to complete. Now, with advanced technology, this type of testing can be completed in a much shorter time frame. Timing of the test results is in the hands of the customers, so we have to wait for each of them to give us the final results. As previously disclosed, we expect the results to be provided at approximately the end of September, depending on customer timing."

where is kaklak?

what is the ticker symbol for the China Dow ETF?

Most trade on US exchanges.

are these Chines stocks trading on US exchage or Shanghia?

whats a boardmark?

China Dow

Going to try to be a mod here and get some interest in going, ihubbers are missing out (me included) on this china mega-bull.

Going to hunt down some more china stocks, they are really blowing away US stocks in % gains...

Boardmark!

China Sun Group High-Tech Co. Signs Contracts With Four More Battery Companies to Begin Testing on Eco-Friendly Product
Press Release
Source: China Sun Group High-Tech Co.
On Wednesday June 24, 2009, 12:08 pm EDT
Buzz up! 0
Print
LIAONING PROVINCE, China, June 24 /PRNewswire-FirstCall/ -- China Sun Group High-Tech Co. (OTC Bulletin Board: CSGH - News), which through its wholly-owned subsidiary Dalian Xinyang High-Tech Development Co. Ltd. ("DLX") has the second largest cobalt series production capacity in the People's Republic of China ("PRC"), announced today that it has entered into contracts with four additional battery production companies to begin testing samples of lithium ion phosphate. A next generation 'green' power source, lithium ion phosphate can be built into batteries that power electric cars, hybrids, scooters, and other state-of-the-art electronic devices.

In addition to DLX's four new testing customers, testing by two of DLX's existing customers, Shandong Zaozhuang and Beijing Zhongke, on the natural attenuation rate curve is nearing completion. Early reports indicate that over the past 45 days, the change of curve has maintained good consistency with a very little decay rate. Shandong Zaozhuang and Beijing Zhongke on May 7th and May 21, 2009 respectively, expanded their relationship with DLX by entering into memorandums of understanding to continue battery development based on lithium ion phosphate materials supplied by DLX.

"Our customers' involvement in testing and feedback helps to ensure the highest quality standards are meet, if not exceeded. Our goal is to help global manufacturers lower their carbon footprint, increase safety and decrease production costs using the latest technologies and materials such as lithium ion phosphate," said China Sun Group CEO Bin Wang. "In addition to growing our customer base and those performing testing, we continue to receive ongoing support and direction from City Council of Dalian, which should help accelerate our time-to-market lithium ion phosphate."

CSGH reports record results. Quarterly Revenue Up 42% to $7.6 Million; Net Income Increases 145% to $1.8 Million -

China Sun Group High-Tech Co. (OTC Bulletin Board: CSGH, "China Sun Group"), which through its wholly-owned subsidiary Dalian Xinyang High-Tech Development Co. Ltd ("DLX") has the second largest cobalt series production capacity in the People's Republic of China ("PRC"), today announced its financial results for the second fiscal quarter ended November 30, 2008. Full details are available on the Company's Quarterly Report filed on Form 10-Q with the SEC at http://www.sec.gov on January 12, 2009.

Revenue for the three months ended November 30, 2008 totaled $7,606,217, an increase of 42% from revenue of $5,357,190 for the comparable period in 2007. Net income for the three months ended November 30, 2008 was $1,809,975, an increase of 145% from $738,482 for the comparable period in 2007. For the second quarter of fiscal 2009, basic and diluted earnings per share were $0.03 compared to $0.01 for the comparable period in fiscal 2008, based on total issued and outstanding 53,422,971 shares of common stock.

Revenue for the six months ended November 30, 2008 was $18,593,108, an increase of 104% from revenue of $9,093,027 for the comparable period in 2007. Net income for the six months ended November 30, 2008 was $4,198,762, an increase of 204% from $1,381,675 for the comparable period in 2007. For the six months ended November 30, 2008, basic and diluted earnings per share were $0.08 compared to $0.03 for the comparable period in fiscal 2008, based on total issued and outstanding 53,422,971 shares of common stock.

Bin Wang, Chief Executive Officer of China Sun Group, said, "We are pleased to report that DLX has continued on an upward growth trend in the second fiscal quarter. While other manufacturers had been scaling down production last quarter, DLX showed continued strength and was able to fill new orders from its inventories on a 'just in time' basis."

"In the first half of fiscal 2009, our net profits grew 204%. Despite the great challenges faced by companies in a depressed economy, DLX has forged ahead and proven its ability to capitalize on new growth opportunities emerging in China and other developing nations. We believe DLX will continue to outperform its competitors in fiscal 2009," concluded Wang.

About China Sun Group

China Sun Group High-Tech Co., ("China Sun Group") produces anode materials used in lithium ion batteries. Through its wholly-owned operating subsidiary, Dalian Xinyang High-Tech Development Co. Ltd ("DLX"), the Company primarily produces cobaltosic oxide and lithium cobalt oxide. According to the China Battery Industry Association, DLX has the second largest cobalt series production capacity in the People's Republic of China. Through its research and development division, DLX owns a proprietary series of nanometer technologies that supply state-of-the-art components for advanced lithium ion batteries. Leveraging its state-of-the-art technology, high-quality product line and scalable production capacity, the Company plans to create a fully integrated supply chain from the primary manufacturing of cobalt ore to finished products, including lithium ion batteries. For more information, visit http://www.china-sun.cn.

CEUA down on weakness

new China Steel Ball play CJGH. news out looks like a player for 08. Fresh and dressed for a brand new year

China Jiangsu Golden Horse Steel Ball Announces Corporate Update
China Jiangsu Golden Horse Steel Ball, Inc. (PINKSHEETS: CJGH) ("Golden Horse" or "the Company"), a leading Chinese manufacturer and supplier of ball bearings, today announced a corporate update.

"The change of our corporate name and ticker symbol on October 5, 2007 marks a new beginning for our Company," said Golden Horse Chairman and President, Qiang Ma. The Company changed transfer agency from American Registrar & Transfer Co. to Global Sentry Equity Transfer Inc.

Golden Horse along with its affiliates and controlled entities is one of the top five manufacturers of steel ball bearings in China. The Company produces over three billion ball bearings annually of various specifications along with its development of over 15 new products, such as stainless steel balls, aluminum balls, and ceramics balls. In addition, the Company continues to export its products to over twenty countries worldwide including the USA, Japan, Brazil, India, and Germany.

Mr. Ma further stated, "Our Company has focused solely on the production of steel balls, since our founding in 1987. Today we are one of China's largest producer and a leading specialized manufacturer in this area. Our high technical standards, our drive for quality improvements, and our efforts to reduce production costs, have earned us respect. In turn, we have always held our customers in the highest regard. We have gained trust with not only leading bearing manufacturers in China, but with bearing manufacturers throughout the world. Our position as a leading company in this field has allowed us to improve both the technology and the standard of steel balls. As always, we strive for the highest goal. Our company goal is to continue to improve our technical skills and to provide the best for society. Golden Horse Steel Ball believes its future will be built by people who combine a desire to improve their own skills with the desire to achieve their best."

Forward-looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future anticipated financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We do not intend to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

For more information, please contact:
Investor Relations Contact:

Tel: 1-866-365-4724
Email: Email Contact
Website: www.goldenhorsesteel.com

http://www.businessweek.com/ap/financialnews/D8T1QIJ86.htm

CHBT ~70% undervalued chinese stock

not big board yet but CSGH has been beat up past several trading sessions...Keep on radar

CEUA up big with $2 mil net income for Q3!!!

CCGY reports wed and they make money.

GA bouncing hard

GA new ipo bouncing

CPSL = dilution

NEW YORK, Oct 31 (Reuters) - The soaring debut of CNinsure (CISG.O: Quote, Profile, Research), a Chinese insurance agency and brokerage, on Wednesday made it the third best first-day performer among Chinese initial public offerings on U.S. stock exchanges so far this year.

American Depositary Shares of CNinsure Inc closed up 58 percent at $25.29, a day after an initial public offering priced above expectations, raising $188 million.

On Tuesday, CNinsure's offering of 11.8 million ADS priced at $16 per share, compared with a forecast range of $13 to $15, which was raised from a range of $11 to $13 a share.

Each ADS represents 20 ordinary shares. Underwriters were led by Morgan Stanley (MS.N: Quote, Profile, Research).

CNinsure, an independent agency which has been in business since 1999, has about 11,0000 sales professionals in outlets operating from eight of China's 22 provinces.

Chief Financial Officer David Tang told Reuters the company plans to expand its network to more parts of the country, including through acquisitions, but did not specify what rate of growth it expects to achieve.

"I could not give you a roadmap, definitely we are looking to expand," he said, adding he believes that, by revenue, CNinsure is the largest domestic insurance agency in China.

From 2000 to 2005, the Chinese insurance market grew by more than 200 percent

anybody long on LONG ? lol

CHLN going nuts... lol

FUQI closed like shit towards end of day
hopefully tomorrow will be HUuuuuuuuuuuuuuger lol

QXM looks to run again and will take XING with it.

This stock is supposedly 75% undervalued. 4 bagger potential IF IF their reports are true.

CHLN a chinese home builder looks good but not much volume yet.

csgh-not big board yet sorry

CHRI Signs Cooperation Contract with Guangzhou Qingping Trade Center; Sees Further Progress in the Herbal Medicine Markets Across Southern China and Southeast Asia

SUINING, China, Oct. 22 /Xinhua-PRNewswire/ -- China Health Resource, Inc. (OTC Bulletin Board: CHRI - News) announced today that it has signed a cooperation contract with Guangzhou Qingping Trade Center (''Qingping''), one of the four biggest herbal medicine and healthcare products markets in China. CHRI will, according to the contract, establish a South China Sales and Logistics Center for Suining Chuan Dahurian Angelica Root (DAR) and related products in Qingping, meanwhile, Qingping will greatly boost the sales of Chuan DAR and related products in the area with its great influence in Southeast Asia's herbal medicine markets.
ADVERTISEMENT


The CHRI South China Sales and Logistics Center is located at the Phase II transaction section of Guangzhou Qingping Trade Center with a 300 square meter first-class office, a 220 square meter exhibition center, and an 1800 square meter international-standard warehousing center. It's a signal of the beginning of the market expansion in South China and Southeast Asia. The South China Sales and Logistics Center is predicted to generate revenue of $2.5 million annually.

Guangzhou Qingping Trade Center has a history of 20 years. It is the biggest trading market and distribution center, as well as the biggest import- export trading port of medicine and healthy food materials. According to the official data, the gross trading revenue of the market in 2006 was $0.4 billion. The daily customer flow is 100,000 people. It is expected that trading revenues will hit $0.66 billion in 2008.

About the Company

China Health Resource, Inc. (CHRI) was incorporated on April 24, 2001. It is one of China's leading industrialized agricultural corporations. CHRI focuses on the production and further processing of Dahurian Angelica Root (DAR), a herb that is widely used and considered to be an important ingredient in Chinese traditional medicines. CHRI's business plan includes distributing DAR and the processed products to exploit a large market in the areas of treatment of pain, swelling and pustule. Good Agricultural Practice (GAP) is a national compulsory criterion for food and drug industries. The goal of GAP is to help agricultural product companies deal with the usual micro-organism harm so as to strengthen agricultural product safety. CHRI has accomplished the GAP certification of Chuan DAR, making the DAR products and related production technology of the Company become the industry criteria.

For more information, please contact:

China Health Resource, Inc.
Tel: +86-825-2391788
343 Suining Zhong Road, Suining, Sichuan, P.R. China
Web: http://www.chinahealthresources.com

CHRI: OTCCC China up 13% today at $.25

any hot chinese *bigboard* plays?

Will be watching NED tomorrow, need to do some more DD. RCH for another swing?

lol, got any good china big boards?

FNIX => Bloated / diluted pig, lol.

What will be the offering price? (NED)

FNIX huge... lol

i like: that it's a china ipo
i dislike; that it's a china ipo ;)

lol... first few days might be hot.

Hmmm, NED? I will radar it, anything CHINA has been HOT!

....ok, just about anything, China ;)

What do you like / dislike about this company, StockScientist?

CSGH posted good 10-QSB numbers today!

Chinese IPO this friday: NED

noah education holdings

possibly a huge one just like STV and RCH

CBPC should run.....nice news!

CBPC news is out

October 15, 2007 - 7:21 AM EST



Company's Partner Completes Trial Production of a New Antiviral Medicine
HANGZHOU, China, Oct. 15 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced today that its partner, Soonfast Pharmaceutical Science & Technology Co., Ltd. ('Soonfast') has successfully completed its trial production of a new antiviral product. This all-natural medicine has been approved in China for external use to treat human papillomavirus ('HPV') and herpes simplex virus ('HSV'). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV up to 90% only in 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33. The sample product is available for distributors now and the commercial product will be available next month.

HPV infection is common across all races and socio-economic groups and is prevalent throughout the world in sexually active persons. HPVs are the most common sexually transmitted viral agents in the United States, infecting up to 20% of people aged 15 to 49. In the last 30 years, the incidence of HPV infection has increased dramatically. Despite the prevalence of HPV, no available drug therapy effectively eliminates HPV infection and replication or prevents HPV-associated malignant progression.

According to the agreement reached with Soonfast in June this year, China Biopharma has the right to distribute this new all-natural antiviral medicine in overseas market. The successful trial production has now quickened some approval process for China Biopharma to launch commercial sales on overseas market including Europe and the United States. The company and Soonfast also plan to jointly conduct studies on its extracts in both China and USA so as to obtain approval necessary for selling this medicine as an over-the-counter drug. The company believes this new medicine would bring in significant revenue and profit in the near future once it is successfully introduced into the market.

About China Biopharma, Inc.

China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines and other pharmaceutical drugs. Leveraging its investment and ownership of local Chinese bio-pharmaceutical companies, and partnerships with international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new world markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.

Safe Harbor Statement

Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These 'forward-looking' statements can generally be identified by words such as 'expect,' 'anticipate,' 'believe,' 'estimate,' 'intend,' 'plan,' and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.

CONTACT:

China Biopharma, Inc.
Tel: +1 (609) 651-8588
Attn. George Ji
ir@chinabiopharma.net
http://www.chinabiopharma.net

SOURCE China Biopharma, Inc.



Source: PR Newswire (October 15, 2007 - 7:21 AM EST)

IPO ALERT NEXT WEEK: NED NED NED NED

Noah Education Holdings (China)
NED

offered price $9.80-$11.80
shares 9.8 mil

PPS has run in past two weeks...perhaps CDGT wants to uplist to AMEX and attain $4 PPS?

got a chart for csgh?